Acute Tubular Necrosis (ATN)
This patient has acute tubular necrosis (ATN), not pre-renal azotemia, despite the clinical history suggesting volume depletion. The urinary indices definitively point to intrinsic renal injury rather than a functional/hemodynamic cause.
Diagnostic Reasoning
The urinary biochemistry is the critical differentiating factor here:
- Urine sodium: 68 mEq/L (markedly elevated, >40)
- Urine osmolality: 220 mOsm/kg (very low, <350)
- Urine specific gravity: 1.009 (assuming the "900" is 1.009, which is inappropriately dilute)
These values are classic for ATN 1. In pre-renal azotemia, you would expect urine sodium <20 mEq/L, urine osmolality >500 mOsm/kg, and concentrated urine with specific gravity >1.020 as the kidneys attempt to conserve sodium and water 1, 2.
The fractional excretion of sodium (FENa) can be calculated from the available data. With a urine sodium of 68 and the degree of creatinine elevation, this would yield an FENa well above 2%, which strongly indicates ATN rather than pre-renal disease 1, 3.
The Lisinopril Factor
The ACE inhibitor (lisinopril) is a critical contributor to this patient's ATN. The FDA labeling explicitly warns that patients with volume depletion are at particular risk of developing acute renal failure on lisinopril 4. The drug label specifically states: "Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with...volume depletion) may be at particular risk of developing acute renal failure on lisinopril" 4.
Pathophysiology
In this clinical scenario:
- Volume depletion from vomiting/diarrhea → decreased renal perfusion
- Lisinopril blocks angiotensin II formation → prevents efferent arteriolar vasoconstriction
- Loss of autoregulation → glomerular filtration pressure drops precipitously
- Prolonged hypoperfusion → tubular cell injury and death → ATN
This represents the transition from functional (pre-renal) to structural (ATN) kidney injury 5. The duration of several days with ongoing volume losses while on an ACE inhibitor allowed progression from reversible hemodynamic AKI to established tubular necrosis.
Why Not Pre-renal?
While the clinical history (GI losses, volume depletion) suggests pre-renal azotemia, the urinary indices trump the clinical story. The kidneys have lost their ability to concentrate urine and conserve sodium—hallmarks of tubular dysfunction, not intact tubules responding to hypoperfusion 1, 2.
The BUN:creatinine ratio (11 mmol BUN ÷ 160 μmol creatinine, converting units ≈ 30.8 mg/dL ÷ 1.8 mg/dL = 17:1) is also not particularly elevated, which would be expected in pure pre-renal states where urea reabsorption is enhanced.
Management Implications
Immediately discontinue lisinopril 4. The FDA labeling states: "Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on lisinopril" 4.
Additional management:
- Volume resuscitation with isotonic fluids (despite ATN being established, optimizing perfusion prevents further injury)
- Avoid all nephrotoxins
- Monitor for complications (hyperkalemia, metabolic acidosis, uremia)
- Serial creatinine monitoring—expect slower recovery than pre-renal (days to weeks vs. hours to days)
- Consider nephrology consultation given the severity (creatinine 160 μmol/L from 60 μmol/L represents >2.5-fold increase = KDIGO Stage 2-3 AKI) 6
Common Pitfall
The major pitfall is assuming that a clinical history of volume depletion automatically means pre-renal azotemia. Many clinicians see GI losses and immediately diagnose pre-renal disease without checking urinary indices. However, prolonged hypoperfusion—especially in the setting of ACE inhibitors—progresses to ATN 5. The urinary indices are essential for distinguishing these entities and have been validated since 1978 1.